98%
921
2 minutes
20
Background: Medication regimen complexity describes multiple characteristics of a patient's prescribed drug regimen. Heart transplant recipients must comply with a lifelong regimen that consists of numerous medications. However, a systematic assessment of medication regimen complexity over time has not been conducted in this, or any other, transplant population.
Objective: The objective of this study was to quantify patient-level medication regimen complexity over time following primary heart transplantation and heart retransplantation, using the validated patient-level Medication Regimen Complexity Index (pMRCI) tool.
Methods: Medication lists were reviewed at transplant discharge and years 1, 3, and 5 post-primary heart transplant, and at transplant discharge and years 1 and 3 post-heart retransplantation. Medications were categorized as transplant-specific, other prescription, and over-the-counter (OTC).
Results: In primary heart transplant recipients (n = 60), mean total medication count was 14.3 ± 3.4 at transplant discharge and did not change significantly over time ( P = 0.64). Transplant-specific medication count decreased significantly from discharge (2.9 ± 0.4) to year 5 (2.3 ± 0.6); P = 0.02. However, 32% of patients were taking 16 or more total medications at year 5 posttransplant. More than 70% of the pMRCI score was attributed to other prescription and OTC medications, which was largely driven by dosing frequency in this cohort. Medication complexity did not differ significantly between heart retransplant recipients (n = 11) and matched primary heart transplant controls (n = 22).
Conclusion: Together, these data highlight the substantial medication burden after heart transplantation and reveal opportunities to address medication regimen complexity in this, and other, transplant populations.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1060028016657552 | DOI Listing |
J Dement Alzheimers Dis
June 2025
Department of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI 02912, USA.
Background/objective: Cyclosporine A and other calcineurin inhibitors have been identified as prospective treatments for preventing Alzheimer's disease. We previously found that calcineurin inhibitors elicit a unique behavioral profile in zebrafish larvae, characterized by increased activity, acoustic hyperexcitability, and reduced visually guided behaviors. Screening a large library of FDA-approved compounds using Z-LaP Tracker revealed that some heart medications produce a similar behavioral profile, suggesting these drugs may exert calcineurin-inhibitor-like effects relevant to prevent-ing or ameliorating Alzheimer's disease.
View Article and Find Full Text PDFAntimicrob Steward Healthc Epidemiol
September 2025
National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT, Australia.
Background: infections (CDI) increased at a large, regional hospital in New South Wales, Australia, in 2021, coinciding with an increase at hospitals Australia wide. We aimed to investigate the association between antibiotic prescribing practices and hospital-acquired CDI at the hospital to inform antimicrobial stewardship (AMS) programs.
Methods: We conducted a retrospective case-control study for the period July 1, 2018, and June 30, 2022.
Rev Cuid
July 2025
Fundación Cardiovascular de Colombia, Piedecuesta, Santander, Colombia. Postgraduate Department in Infectious Disease, Universidad de Santander, Santander, Colombia. E-mail: Fundación Cardiovascular de Colombia Santander Colombia
Introduction: The inappropriate use of antibiotics in intensive care units poses risks, such as increased infections caused by multidrug-resistant bacteria and adverse reactions. The World Health Organization's strategy, named Access, Watch, and Reserve, aims to mitigate these risks by categorizing antibiotics into these categories.
Objective: To characterize antibiotic consumption in the adult population of intensive care units during the first quarter of 2023.
Rev Cardiovasc Med
August 2025
Department of Neonatology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 510080 Guangzhou, Guangdong, China.
Background: This study aimed to determine the optimal dosages of prostaglandin E1 required to maintain a patent ductus arteriosus (PDA) in infants with transposition of the great arteries (TGA) based on point-of-care ultrasound (POCUS) findings.
Methods: Infants with TGA were recruited from two groups (the historical control group and the POCUS group that received POCUS in combination with pulse oximetry saturation (SpO) to titrate the dose of prostaglandin E1 (PGE1)).
Results: A total of 150 patients were included in this study.
Phys Imaging Radiat Oncol
July 2025
Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy.
Biology-guided voxel-level inverse prescription mapping for dose painting (DP) using diffusion-weighted magnetic resonance imaging was evaluated for technical feasibility in proton therapy for 10 skull-base chordoma patients. Patient-specific DP prescriptions were generated from tumour cellularity and implemented in a clinical treatment planning system. Compared with uniform plans, DP achieved lower conformity (although >97 %), improved target dose metrics, reduced doses to most organs at risk, and increased tumour control probability without exceeding clinical constraints.
View Article and Find Full Text PDF